June 01, 2016 04:10
Uni Pharma Co., Ltd., which specializes in the sales of international pharmaceutical products, has been approved by the Food and Drug Administration (TFDA) in 2014 and has been adopted by 11 medical centers in China, and has also received long-term orders from the European Union in overseas markets. At the beginning of May, 108 sets of DR-70 were exported to the European Union, and a single export exceeded the 100 sets mark.
Lin Liangguang, general manager of Uni Pharma, said that DR-70 continues to grow, and it is expected that a single export will reach 200 sets from July, with an amount of more than 100,000 US dollars, and a single export in the fourth quarter is more likely to grow to 700 sets, and there will be opportunities to grow multiple times from 2017 to 2018. Uni Pharma will carry out product inspection and registration programs in the United States and Canada, and if it can be approved for marketing in major countries around the world, it will indirectly prove the clinical value of DR-70 products. The rapid growth of this product is mainly due to the value of clinical trials confirming its use in colorectal cancer postoperative tracking, and the beginning of insurance coverage in EU countries.
The tumor marker DR-70 in vitro diagnostic reagent is also in clinical trials in China, with a total of more than 1,000 patients enrolled and will be followed up for 6 months. In August 2015, Uni Pharma completed the product quality inspection at the Beijing Quality Inspection Institute and obtained the qualification report. Immediately launched a multi-center clinical trial in three tertiary hospitals in two regions, hoping to complete the case by the end of 2016, and complete the clinical trial report in the first half of 2017 and submit it to the China Food and Drug Administration for approval, and it is expected that the Chinese market will enter a new era.
In addition, Uni Pharma has two agent products that obtained the second-level medical device license from the Ministry of Health and Welfare in December last year, including minimally invasive electrocautery surgery (Radio Frequency Ablation; RFA) is a new medical device that can be used for thyroid nodules to reduce the side effects of surgery, and the other is the fecal occult blood test strip (EZ-Detect), which is a great boon for colorectal cancer patients.
Uni Pharma revenue in 104 years is 137 million yuan, and it is expected to be publicly issued in the fourth quarter of this year.
(Business Times)
